Percutaneous

NeurAxis Reports Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 20, 2023
Policy, Adolescence, Research, Neuraxis, Percutaneous, Hospital, Record, Abdominal pain, RED, Disability, University, Cyproheptadine, Growth, Publication, Patient, CareFirst BlueCross BlueShield, Amitriptyline, FAPD, Video game

CARMEL, Ind., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • CARMEL, Ind., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today reported financial results for the third quarter ended September 30, 2023.
  • Gross margin totaled 85.9% in the third quarter of 2023, compared to 89.1% in the third quarter of 2022.
  • Selling expenses for the third quarter of 2023 were $64.2 thousand, compared to $81.6 thousand in the third quarter of 2022.
  • General and administrative expenses for the third quarter of 2023 were $3,323.4 thousand, compared to $1,586.5 thousand in the third quarter of 2022.

Orthofix Announces First Cases and Full Commercial Launch of the 7D FLASH Navigation System Percutaneous Module 2.0 for Minimally Invasive Surgery

Retrieved on: 
Monday, August 28, 2023
Health, Medical Devices, Surgery, Physical Therapy, Other Health, General Health, Biotechnology, Minimally invasive procedure, Radiation, Surgeon, Percutaneous, Spine, Multimedia, Patient, MIS, Safety, Satellite navigation device

Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the full commercial launch and successful completion of the first cases in the U.S. with the 7D FLASH™ Navigation System Percutaneous Module 2.0.

Key Points: 
  • Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the full commercial launch and successful completion of the first cases in the U.S. with the 7D FLASH™ Navigation System Percutaneous Module 2.0.
  • The Percutaneous Module 2.0 provides new planning features and increased functionality for the 7D FLASH Navigation System, allowing Orthofix to further serve the Minimally Invasive Surgery (MIS) spine market, estimated at approximately $1.8 billion in the U.S.1
    This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20230828212653/en/
    Image of the 7D FLASH™ Navigation System with the Percutaneous Module 2.0 for minimally invasive surgeries.
  • This new application addresses the important MIS spine navigation market and further positions the 7D FLASH Navigation System to be the navigation choice for a wide range of institutions from teaching hospitals to ambulatory surgery centers.”
    To learn more about the 7D FLASH Navigation System, please visit SeaSpine.com or 7DSurgical.com .

CHA Hollywood Presbyterian Medical Center Ranked No. 2 in California for Coronary Interventional by Healthgrades

Retrieved on: 
Wednesday, February 8, 2023
Emergency medical services, Physician, Hospital, Artery, U.S. National STEMI Receiving Centers, Protected percutaneous coronary intervention, Patient, STEMI, Healthgrades, Percutaneous, Emergency department, Percutaneous coronary intervention, Heart, CHA, LOS, Angioplasty, Nursing

LOS ANGELES, Feb. 8, 2023 /PRNewswire-PRWeb/ -- CHA Hollywood Presbyterian Medical Center (CHA HPMC), a member of CHA Health Systems, a global network providing a full spectrum of dynamic healthcare services, has been ranked as the second best hospital in California for coronary interventional procedures, according to a new analysis released by Healthgrades, the leading online resource that connects consumers, physicians, and health systems. Additionally, CHA HPMC has been recognized as one of America's 100 Best Hospitals for Coronary Intervention for two years in a row (2022-2023), America's 100 Best for Spine Surgery for three years in a row (2021-2023), and a recipient of Orthopedic Surgery Excellence Award (2023).

Key Points: 
  • LOS ANGELES, Feb. 8, 2023 /PRNewswire-PRWeb/ -- CHA Hollywood Presbyterian Medical Center (CHA HPMC), a member of CHA Health Systems, a global network providing a full spectrum of dynamic healthcare services, has been ranked as the second best hospital in California for coronary interventional procedures, according to a new analysis released by Healthgrades, the leading online resource that connects consumers, physicians, and health systems.
  • Percutaneous coronary intervention is a minimally invasive, non-surgical procedure used to treat blockages in the coronary (heart) arteries and improve blood flow to the heart.
  • Hospitals ranked among the top in the state by Healthgrades are recognized for providing patients with superior clinical outcomes in coronary intervention procedures, including angioplasty with stent.
  • For the state ranking analysis, Healthgrades evaluated clinical performance for nearly 4,500 hospitals nationwide focusing on 18 key specialties across a mix of chronic, urgent, and surgical areas.

SUPIRA MEDICAL ANNOUNCES SUCCESSFUL FIRST-IN-HUMAN USE OF ITS NEXT GENERATION PERCUTANEOUS VENTRICULAR ASSIST DEVICE

Retrieved on: 
Friday, September 16, 2022
Safety, Trial of the century, LOS, Risk, Angioplasty, Percutaneous, Coronary artery disease, DRS, Patient, University of California, Davis, Physician, University Medical Center, Disease, CEO, Solution, CS, Cardiogenic shock, Hemodynamics, Heart, Interventional cardiology, University, Structural heart disease, Medical device, Medicine

LOS GATOS, Calif., Sept. 16, 2022 /PRNewswire/ -- Supira Medical, Inc., a Shifamed portfolio company focused on developing the next-generation solution for mechanical circulatory support, announced today it has initiated its first-in-human clinical study performed by principal investigator, Adrian Ebner, M.D., Head of the Cardiovascular Department at the Italian Hospital Asuncion Paraguay. The prospective, single-arm, single-center study will evaluate the safety and performance of Supira's low-profile, high-flow percutaneous ventricular assist device (pVAD) to support cardiovascular hemodynamics in patients undergoing high-risk percutaneous coronary interventions (HRPCI).

Key Points: 
  • The prospective, single-arm, single-center study will evaluate the safety and performance of Supira's low-profile, high-flow percutaneous ventricular assist device (pVAD) to support cardiovascular hemodynamics in patients undergoing high-risk percutaneous coronary interventions (HRPCI).
  • "Today marks an important milestone as Supira transitions to a clinical-stage company," commented Dr. Nitin Salunke, President and CEO of Supira Medical.
  • Percutaneous ventricular assist devices are used during stent placement or angioplasty to provide mechanical support for high-risk patients with severe coronary artery disease or comorbidities.
  • Supira Medical, a privately held portfolio company of Shifamed, is focused on development of a next generation percutaneous ventricular assist device for use in high-risk patients undergoing interventional procedures.

Co-Author of the Karolinska 1000 Consecutive MANTA® Vascular Closure Device Study to Present Learnings at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Conference

Retrieved on: 
Thursday, September 15, 2022
Weck, Health, MANTA, Karolinska Institute, NYSE, Canadian International Council, SAFE, Anesthesia, VCDS, CRF, Percutaneous, Device, LMA, Interventional cardiology, TAVI, U.S. Securities and Exchange Commission, Patient, Emergency medicine, Karolinska University Hospital, Solution, Annual report, Clinical trial, Teleflex, VCD, International Journal of Cardiology, Security (finance), 1048, Observational study, GLOBE, Prostatic urethral lift, Urology, Catheter, Veni, vidi, vici, TFX, TCT, Radiology, MARVEL, Medical device, Medical imaging, Cardiology, Pilling, QuikClot

TCT is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the world's foremost educational forum specializing in interventional cardiovascular medicine.

Key Points: 
  • TCT is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the world's foremost educational forum specializing in interventional cardiovascular medicine.
  • The findings of our study indicate that the MANTA Device is easy to learn and has a short learning curve, which is in line with our user experience.
  • The MANTA Device is the first commercially available biomechanical vascular closure device designed specifically for large bore femoral arterial access site closure.
  • Percutaneous plug-based vascular closure device in 1000 consecutive transfemoral transcatheter aortic valve implantations.

Teleflex Announces Health Canada Approval of MANTA® Vascular Closure Device

Retrieved on: 
Wednesday, May 18, 2022
Hemostasis, Population, General manager, U.S. Securities and Exchange Commission, Percutaneous, LMA, MD, MANTA, SAFE, Weck, Patient, TFX, Solution, Health, Emergency medicine, Â, Anesthesia, TEVAR, Clinical trial, Urology, Prostatic urethral lift, IDE, Hospital, Vascular closure device, TAVR, Health Canada, Security (finance), Device, Radiology, NYSE, Annual report, GLOBE, Medical device, Medical imaging, Teleflex, Pilling, QuikClot

WAYNE, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today has announced that it received Health Canada approval for the MANTA Vascular Closure Device the first commercially available biomechanical vascular closure device designed specifically for large bore femoral arterial access site closure.1 This approval marks an important milestone in the regulatory plan to expand the availability of the MANTA Device globally and provides access to another uniquely designed device from Teleflex to Canadian clinicians.

Key Points: 
  • WAYNE, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today has announced that it received Health Canada approval for the MANTA Vascular Closure Device the first commercially available biomechanical vascular closure device designed specifically for large bore femoral arterial access site closure.1 This approval marks an important milestone in the regulatory plan to expand the availability of the MANTA Device globally and provides access to another uniquely designed device from Teleflex to Canadian clinicians.
  • Our team has been working diligently to obtain this approval and were confident that Health Canada would recognize the benefits of the MANTA Device, said Scott Holstine, President and General Manager of the Teleflex Interventional Business Unit.
  • Percutaneous vascular closure obtained with the MANTA Device without the use of unplanned endovascular or surgical intervention.
  • A single MANTA Vascular Closure Device was deployed in 99.6% of subjects in IDE trial.

Global Percutaneous Transluminal Angioplasty Balloons Catheter Market Report to 2028 - Size, Share, Outlook, and Opportunity Analysis - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 26, 2022
Health, Other Health, Neck, Groin, Marketing, Medtronic, Percutaneous, Angioplasty, Brain, CAGR, Region, PTA, Knee, Application, US, Cerebral arteries, Plaque, Wrist, Chameleon, Common carotid artery, Industry, Arm, Atherosclerosis, Medical imaging

The "Percutaneous Transluminal Angioplasty Balloons Catheter Market, by Type, by Material, by Application, by Diameter Size, by End User and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Percutaneous Transluminal Angioplasty Balloons Catheter Market, by Type, by Material, by Application, by Diameter Size, by End User and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • Percutaneous transluminal angioplasty (PTA) is a procedure that opens up blocked peripheral arteries due to plaque build-up (atherosclerosis).
  • A series of x-ray images are taken to clearly view the narrowed artery after the catheter is advanced into the narrowed artery.
  • Increasing launches of angioplasty balloons catheter products in the market by key players are expected to drive the global percutaneous transluminal angioplasty balloons catheter market growth during the forecast period.

Venus Medtech Obtains CE Certification for VenusP-Valve™

Retrieved on: 
Friday, April 15, 2022
Venus, Patient, Marketing, Population, Percutaneous, Heart failure, Fluoroscopy, Tetralogy of Fallot, TAP, Hospital, NYHA, Evelina London Children's Hospital, Safety, Union, Medical imaging, EU

HANGZHOU, China, April 15, 2022 /PRNewswire/ --On April 8th, a Chinese company named Venus Medtech announced that its self-developed VenusP-ValvePercutaneous prosthetic pulmonary valve replacement system was approved by the European Union (CE) for marketing.

Key Points: 
  • HANGZHOU, China, April 15, 2022 /PRNewswire/ --On April 8th, a Chinese company named Venus Medtech announced that its self-developed VenusP-ValvePercutaneous prosthetic pulmonary valve replacement system was approved by the European Union (CE) for marketing.
  • VenusP-Valveis the first slef-expanding valve in Europe for the treatment of patients with right ventricular outflow tract disorder (RVOTD) following transannular repair (TAP).
  • In 2011, Venus Medtech invited international doctors to jointly develop VenusP-Valve.
  • In September 2016, Venus Medtech and Evelina London Children's Hospital officially launched the VenusP-Valve CE marking certification pre-market clinical trial.

Outlook on the Blade Remover Global Market to 2028 - Focus on Safety Enhancement and Surgical Procedures Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Monday, March 21, 2022
Surgery, Health, Risk, CAGR, Bleeding, Growth, Compliance, Hospital, Incidence, Percutaneous, Injury, Finger, Industry, Time, COVID-19, Patient, Infection, Tissue paper, Medical device, Marketing

A conventional surgical blade includes a reusable sterile handle with a tang at one end attached to a replaceable slotted blade.

Key Points: 
  • A conventional surgical blade includes a reusable sterile handle with a tang at one end attached to a replaceable slotted blade.
  • Based on product type, the global blade remover market has been segmented into single use blade removers and multiple use blade removers.
  • Based on end-user/ application, the global blade remover market is segmented into hospitals, ambulatory surgical centers and others.
  • Scrutinize in-depth market trends and outlook in Europe coupled with the factors driving the market, as well as those hindering it.

Latest analysis shows VASCEPA® (icosapent ethyl) significantly lowered the risk of potentially fatal cardiovascular events in patients with prior percutaneous coronary intervention

Retrieved on: 
Thursday, March 10, 2022
NASDAQ, Heart, JAHA, MI, American Heart Association, Professional corporation, Percutaneous, Risk, Percutaneous coronary intervention, Prior, PCI, CV, Infarction, Hospital, IPE, Angina, Blood, Journal, GLOBE, Journal of the American Heart Association, Patient, NNT, Stroke, Population, Myocardial infarction, History, Pharmaceutical industry

DUBLIN, Ireland and BRIDGEWATER, N.J., March 10, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the publication of new REDUCE-IT data analysis that helps support the clinical benefits of icosapent ethyl (IPE) for patients who have received a percutaneous coronary intervention (PCI) and are at high risk for experiencing a stroke, heart attack, or fatal cardiovascular (CV) event.(1)

Key Points: 
  • This publication furthers the clinical evidence base for icosapent ethyl treatment in patients with prior PCI at risk of a recurrent CV event.
  • (1)
    There is evidence suggesting that patients who have a prior PCI are at a heightened risk of subsequent CV events compared with other patients with CV risk factors.
  • Treatment with Icosapent Ethyl to Reduce Ischemic Events in Patients with Prior Percutaneous Coronary Intervention - Insights from REDUCE-IT PCI.
  • Statin therapy has been shown to control LDL-C, thereby reducing the risk of cardiovascular events by 25-35%.ii Significant cardiovascular risk remains after statin therapy.